<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432022000100027</article-id>
<article-id pub-id-type="doi">10.7399/fh.11638</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Calidad de vida relacionada con la salud en pacientes con artritis reumatoide, artritis psoriásica y espondilitis anquilosante tratados con certolizumab pegol]]></article-title>
<article-title xml:lang="en"><![CDATA[Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sarobe]]></surname>
<given-names><![CDATA[Maite]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arrondo]]></surname>
<given-names><![CDATA[Amaya]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ibarrondo]]></surname>
<given-names><![CDATA[Oliver]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4 "/>
<xref ref-type="aff" rid="Af5"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4 "/>
<xref ref-type="aff" rid="Af5"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Complejo Hospitalario de Navarra Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Pamplona ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Organización Sanitaria Alto Deba Unidad de Investigación AP-OSIs Osakidetza]]></institution>
<addr-line><![CDATA[Arrasate-Mondragón Gipuzkoa]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Investigación Sanitaria Biodonostia  ]]></institution>
<addr-line><![CDATA[San Sebastián ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Red de Investigación en Servicios de Salud en Enfermedades Crónicas  ]]></institution>
<addr-line><![CDATA[Bilbao ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Alto Deba Unidad de Gestión Sanitaria ]]></institution>
<addr-line><![CDATA[Mondragón Gipuzkoa]]></addr-line>
<country>España</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,RS-Statistics  ]]></institution>
<addr-line><![CDATA[Arrasate-Mondragón Gipuzkoa]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<volume>46</volume>
<numero>1</numero>
<fpage>27</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432022000100027&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432022000100027&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432022000100027&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Las enfermedades articulares inflamatorias causan dolor y discapacidad. El objetivo fue medir la calidad de vida de los pacientes con artritis reumatoide, artritis psoriásica, espondilitis anquilosante en tratamiento con certolizumab pegol y compararla con la de la población general.  Método: Con un diseño transversal se recogieron variables sociodemográficas y clínicas, adherencia al tratamiento y calidad de vida mediante el cuestionario Euroqol-5d-5L (EQ-5D). La calidad de vida de la población general se obtuvo de la Encuesta Nacional de Salud. El EQ-5D se analizó en ambos grupos mediante modelos de dos partes que miden la probabilidad de tener una salud perfecta y la disutilidad causada por la enfermedad.  Resultados: La muestra incluyó 59 pacientes con una adherencia alta (92,3%). La utilidad media fue de 0,78 y el dolor resultó la dimensión más afectada. La reducción de utilidad (índice EQ-5D) de los pacientes con enfermedades articulares inflamatorias respecto a la población general fue de 0,127.  Conclusiones: Los pacientes muestran una calidad de vida significativamente menor que la población general a pesar del buen control de la enfermedad. Los modelos de dos partes facilitan la interpretación de los estudios de calidad de vida mediante EQ-5D.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Inflammatory joint diseases cause pain and disability. The objective of this study was to measure the quality of life of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with certolizumab pegol and compare the results with those of the general population.  Method: Using a cross-sectional design and sociodemographic and clinical variables, adherence to treatment and quality of life data were collected using the Euroqol-5d-5L (EQ-5D) questionnaire. The quality of life of the general population was obtained from the Spanish National Health Survey. Answers to the EQ-5D questionnaire were analyzed in both groups using two-part models, which measure the probability of having perfect health as well as the disutility caused by the disease.  Results: The sample included 59 patients with high adherence (92.3%). The mean utility value was 0.78 and pain was the most affected dimension. The reduction in utility (EQ-5D index) of patients with inflammatory joint disease as compared to the general population was 0.127.  Conclusions: The subjects of the study showed a significantly lower quality of life than the general population despite effective control of the disease. Two-part models facilitate the interpretation of quality-of-life studies using the EQ-5D.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Calidad de vida]]></kwd>
<kwd lng="es"><![CDATA[Adherencia a la medicación]]></kwd>
<kwd lng="es"><![CDATA[Certolizumab pegol]]></kwd>
<kwd lng="es"><![CDATA[Medidas de resultado informadas por el paciente]]></kwd>
<kwd lng="es"><![CDATA[Artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[Artritis psoriásica]]></kwd>
<kwd lng="es"><![CDATA[Espondilitis anquilosante]]></kwd>
<kwd lng="en"><![CDATA[Health-related quality of life]]></kwd>
<kwd lng="en"><![CDATA[Medication adherence]]></kwd>
<kwd lng="en"><![CDATA[Certolizumab pegol]]></kwd>
<kwd lng="en"><![CDATA[Patient-reported outcome measures]]></kwd>
<kwd lng="en"><![CDATA[Arthritis, rheumatoid]]></kwd>
<kwd lng="en"><![CDATA[Arthritis, psoriatic]]></kwd>
<kwd lng="en"><![CDATA[Spondylitis, ankylosing]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Villaverde]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ballina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gabriel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Laffon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of rheumatoid arthritis in the general population of Spain]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2002</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>88-95</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Estebaranz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Zarco-Montejo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Samaniego]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[García-Calvo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<collab>PREVAL Study Group</collab>
<article-title xml:lang=""><![CDATA[Prevalence and clinical features of psoriatic arthritis in psoriasis patients in Spain. Limitations of PASE as a screening tool]]></article-title>
<source><![CDATA[Eur J Dermatol]]></source>
<year>2015</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-63</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bollow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Remlinger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Eggens]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Rudwaleit]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Distler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1998</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-67</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aaltonen]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Virkki]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Malmivaara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Konttinen]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Nordström]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2012</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="">
<collab>Agencia Europea del Medicamento</collab>
<source><![CDATA[Ficha técnica o resumen de las características del producto Cimzia]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Goñi]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Oppe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramallo-Fariña]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto-Prades]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2018</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>596-604</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheiman-Elazary]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shourt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ellashof]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cameron-Hay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2016</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>512-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrospide]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Goñi]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Pechlivanoglou]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of two-part models and Cholesky decomposition to incorporate covariate-adjusted utilities in probabilistic cost-effectiveness models]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2020</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrospide]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Machón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Goñi]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ibarrondo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inequalities in health-related quality of life according to age, gender, educational level, social class, body mass index and chronic diseases using the Spanish value set for Euroquol 5D-5L questionnaire]]></article-title>
<source><![CDATA[Health Qual Life Outcomes]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosa-Gonçalves]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bernardes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life and functional capacity in patients with rheumatoid arthritis - Cross-sectional study]]></article-title>
<source><![CDATA[Reumatol Clin]]></source>
<year>2018</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>360-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibarra Barrueta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Morillo Verdugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Lo que debes saber sobre la adherencia al tratamiento]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soliman]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Ashcroft]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Lunt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Symmons]]></surname>
<given-names><![CDATA[DPM]]></given-names>
</name>
<name>
<surname><![CDATA[Hyrich]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2011</year>
<volume>70</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>583-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
